Zhong He

Zhong He

Auto-generated profile, based on publicly available information

Zhong He

James P. Allison Institute, University of Texas MD Anderson Cancer Hospital, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
RCRafael Cubas
Rafael Cubas
JGJulien Van Grevenynghe
Julien Van Grevenynghe
SWSaintedym Wills
Saintedym Wills
LKLela Kardava
Lela Kardava
BSBrian H. Santich
Brian H. Santich
EHElias K. Haddad
Elias K. Haddad
Despite the overwhelming benefits of antiretroviral therapy (ART) in curtailing viral load in HIV-infected individuals, ART does not fully restore cellular and humoral immunity. HIV-infected individuals under ART show reduced responses to vaccination and infections and are unable to mount an effective antiviral immune response upon ART cessation. Many factors contribute to these defects, including persistent inflammation, especially in lymphoid tissues, where T follicular helper (Tfh) cells instruct and help B cells launch an effective humoral immune response. In this study we investigated the phenotype and function of circulating memory Tfh cells as a surrogate of Tfh cells in lymph nodes and found significant impairment of this cell population in chronically HIV-infected individuals, leading to reduced B cell responses. We further show that these aberrant memory Tfh cells exhibit an IL-2–responsive gene signature and are more polarized toward a Th1 phenotype. Treatment of functional memory Tfh cells with IL-2 was able to recapitulate the detrimental reprogramming. Importantly, this defect was reversible, as interfering with the IL-2 signaling pathway helped reverse the abnormal differentiation and improved Ab responses. Thus, reversible reprogramming of memory Tfh cells in HIV-infected individuals could be used to enhance Ab responses. Altered microenvironmental conditions in lymphoid tissues leading to altered Tfh cell differentiation could provide one explanation for the poor responsiveness of HIV-infected individuals to new Ags. This explanation has important implications for the development of therapeutic interventions to enhance HIV- and vaccine-mediated Ab responses in patients under ART.

20 May 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
Bilal SiddiquiBilal Siddiqui
Bilal Siddiqui
NPNicolas Palaskas
Nicolas Palaskas
SBSreyashi Basu
Sreyashi Basu
YDYibo Dai
Yibo Dai
ZHZhong He
Zhong He
SSSumit K. Subudhi
Sumit K. Subudhi
Immune checkpoint therapies (ICT) can induce life-threatening immune-related adverse events, including myocarditis and myositis, which are rare but often concurrent. The molecular pathways and immune subsets underlying these toxicities remain poorly understood. To address this need, we performed single-cell RNA sequencing of heart and skeletal muscle biopsies obtained from living patients with cancers treated with ICTs and admitted to the hospital with myocarditis and/or myositis (overlapping myocarditis plus myositis, n = 10; myocarditis-only, n = 1) or ICT-exposed patients ruled out for toxicity utilized as controls (n = 9). All biopsies were obtained within 96 hours of clinical presentation. Analyses of 58,523 cells revealed CD8+ T cells with a cytotoxic phenotype expressing activation/exhaustion markers in both myocarditis and myositis. Furthermore, the analyses identified a population of myeloid cells expressing tissue-resident signatures and FcγRIIIa (CD16a), which is known to bind IgG and regulate complement activation. Immunohistochemistry of affected cardiac and skeletal muscle tissues revealed protein expression of pan-IgG and complement product C4d, which were associated with the presence of high-titer serum autoantibodies against muscle antigens in a subset of patients. We further identified a population of inflammatory IL1B+TNF+ myeloid cells specifically enriched in myocarditis and associated with greater toxicity severity and poorer clinical outcomes. These results provide insight into the myeloid subsets present in human immune-related myocarditis and myositis tissues and nominate new targets for investigation into rational treatments to overcome these high-mortality toxicities. See related Spotlight by Fankhauser et al., p. 954

8 October 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
ALAlexander L Ling
Alexander L Ling
JGJennifer Gantchev
Jennifer Gantchev
MPMichael C Prabhu
Michael C Prabhu
SBSreyashi Basu
Sreyashi Basu
RARyuhjin Ahn
Ryuhjin Ahn
ACAntonio Chiocca
Antonio Chiocca
Recurrent glioblastoma (rGBM) remains incurable. One barrier to the development of effective rGBM therapies is the difficulty in collecting posttreatment tumor tissue. Serial multiomic assays from longitudinal rGBM biopsies may uncover tumor responses to a treatment. Here, we obtained 97 serial rGBM biopsy cores over 4 months from the first two patients participating in a clinical trial of repeated intratumoral dosing of the immunotherapeutic agent CAN-3110. Multiomic analysis of the biopsy cores revealed therapeutic effects, including longitudinal and spatial reshaping of the rGBM’s microenvironment, expansion of new T cell tissue-resident effector memory clonotypes against CAN-3110 epitopes and other undetermined antigens, and expression of human leukocyte antigen (HLA)–presented immunopeptides, including cancer testis antigens. Moreover, serial integrated multimodal analyses provided evidence of therapeutic responses to CAN-3110 despite traditional magnetic resonance imaging indicating progression. Clinically, the two treated patients achieved a pathologic response or stable clinical disease, respectively. These results show the value of longitudinal tissue sampling to understand rGBM’s evolution during administration of an investigational therapy.

25 March 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CPCandice C. Poon
Candice C. Poon
SHShelley M. Herbrich
Shelley M. Herbrich
YCYulong Chen
Yulong Chen
AHAnwar Hossain
Anwar Hossain
GFGregory N. Fuller
Gregory N. Fuller
PSPadmanee Sharma
Padmanee Sharma
Microvascular proliferation (MVP) is a disease-defining hallmark of glioblastoma and other World Health Organization grade 4 gliomas. MVP also serves as a poor prognostic marker in various solid tumors. Despite its clinical significance, the mechanisms and biological consequences of MVP are controversial and remain unclear. In this study, we performed single-cell RNA sequencing on paired CD45−CD105+ vascular/perivascular stromal cells (PVSC) and CD45+CD105± immune cells from 16 primary glioma patient samples, both with and without MVP. This analysis revealed the presence of developmentally related mesenchymal stem cells alongside cancer-associated fibroblasts, pericytes, fibromyocytes, and smooth muscle cells within the CD45−CD105+ compartment. RNA velocity analysis identified PDGFRB as a putative driver gene guiding mesenchymal stem cells toward more mature PVSCs in the context of MVP. Signaling network analysis and digital spatial profiling uncovered interactions between PDGFRB+ PVSCs and immunosuppressive myeloid cell subsets enriched in the perivascular niche, suggesting targetable receptor–ligand interactions. Additionally, a gene signature of MVP-associated PVSCs from gliomas predicted worse prognosis in multiple other solid tumors. This study provides a transcriptomic cell atlas of PVSCs and immune cells in glioma, helping to refine the biological model of MVP which has traditionally focused on endothelial cells.

4 June 2025
Verified
Other
Open access
PDF file
CPCandice C. Poon
Candice C. Poon
SHShelley M. Herbrich
Shelley M. Herbrich
YCYulong Chen
Yulong Chen
AHAnwar Hossain
Anwar Hossain
GFGregory N. Fuller
Gregory N. Fuller
PSPadmanee Sharma
Padmanee Sharma
Fig. S12. Cross referencing of the fatty acid metabolism Hallmark gene set with all CellChat signaling pathways upregulated in our dataset to investigate metabolism-associated PVSC interactions with immune cells. a. Expression of the Hallmark gene set for fatty acid metabolism in immune cells. HLA-DRAlo suppressive monocytes and brain-resident perivascular macrophages exhibited the highest expression of this gene set. b. All CellChat signaling pathways associated with the fatty acid metabolism Hallmark gene set. c. Chord diagram representing the interaction of ligands-and receptors in the BMP pathway (the pathway with the highest overlap between the fatty acid metabolism Hallmark gene set and upregulated CellChat signaling pathways). Ligands are listed on the bottom half of the chord diagram, while receptors are listed on the top half. Cell types are indicated in the legend to the right. The total number of interactions shown for each cell type is directly proportional to the contribution to this signaling pathway by a particular cell type. d. Chord diagram representing the interaction of ligands-and receptors in the THBS pathway (the pathway with the second highest overlap between the fatty acid metabolism Hallmark gene set and upregulated CellChat signaling pathways).

4 June 2025
Verified
Other
Open access
PDF file
CPCandice C. Poon
Candice C. Poon
SHShelley M. Herbrich
Shelley M. Herbrich
YCYulong Chen
Yulong Chen
AHAnwar Hossain
Anwar Hossain
GFGregory N. Fuller
Gregory N. Fuller
PSPadmanee Sharma
Padmanee Sharma
Fig. S8. Automated quantitative analysis of CD105+PDGFRβ+ cells in regions with MVP, regions without MVP, and regions adjacent to MVP that were normal-appearing. CD105+PDGFRβ+ cells are associated with MVP (p = 0.0073**, unpaired t-test with Welch’s correction), indicating that in addition to morphological expansion, the frequency of CD105+PDGFRβ+ cells is also increased under MVP conditions.